ArticleApplied biochemistry and biotechnology2022
Fabrication of Mesoporous Silica Nanoparticle-Incorporated Coaxial Nanofiber for Evaluating the In Vitro Osteogenic Potential.
Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 10 citations in OpenAlex.
- Electrospun PVA Fibers for Drug Delivery: A Review.Polymers · 2023Review
- Electrospun Nanofiber-Based Bioinspired Artificial Skins for Healthcare Monitoring and Human-Machine Interaction.Biomimetics (Basel, Switzerland) · 2023Review
- Multifunctional Scaffolds Based on Emulsion and Coaxial Electrospinning Incorporation of Hydroxyapatite for Bone Tissue Regeneration.International journal of molecular sciences · 2022Review
- Polycaprolactone/Gelatin/Hydroxyapatite Electrospun Nanomembrane Materials Incorporated with Different Proportions of Attapulgite Synergistically Promote Bone Formation.International journal of nanomedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most important role of tissue engineering is to develop a biomaterial with a property that mimics the extracellular matrix (ECM) by enhancing the lineage-specific proliferation and differentiation with favorable regeneration property to aid in new tissue formation. Thus, to develop an ideal scaffold for bone repair, we have fabricated a composite nanofiber by the coaxial electrospinning technique. The coaxial electrospun nanofiber contains the core layer, consisting of polyvinyl alcohol (PVA) blended with oregano extract and mesoporous silica nanoparticles (PVA-OE-MSNPs), and the shell layer, consisting of poly-ε-caprolactone blended with collagen and hydroxyapatite (PCL-collagen-HAP). We evaluated the physicochemical properties of the nanofibers using X-ray diffraction (XRD), thermogravimetric analysis (TGA), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR). In vitro biocompatibility, cell adhesion, cell viability, and osteogenic potential were evaluated by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenlytetrazolium bromide (MTT), calcein AM, and alkaline phosphatase (ALP) activity and Alizarin Red staining in NIH 3T3/MG-63 cells. The results showed that the nanoparticle-incorporated coaxial nanofiber was observed with bead-free, continuous, and uniform fiber morphology with a mean diameter in the range of 310 ± 125 nm. From the biochemical studies, it is observed that the incorporation of nanofiber with HAP and MSNPs shows good swelling property with ideal porosity, biodegradation, and enhanced biomineralization property. In vitro results showed that the scaffolds with nanoparticles have higher cell adhesion, cell viability, ALP activity, and mineralization potential. Thus, the fabricated nanofiber could be an appropriate implantable biomaterial for bone tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.